We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Rectangle Image
News

SII, 3Scan Corp Announce Partnership

Rectangle Image
News

SII, 3Scan Corp Announce Partnership

Read time:
 

System Imagination, Inc.(SII) has announced a partnership with 3Scan, Inc. of San Francisco, California. This partnership combines 3Scan’s 3dimensional reconstructive imaging process while sectioning tissue samples with the integrative genomic and multiscalar data analysis services offering by SII. This partnership will result in a comprehensive, multiscalar, molecularly characterized, 3D high resolution analysis of tissue samples for the Healthcare and Life Sciences.

“We have been building key partnerships with transformative companies to launch this ultrahigh definition solution for translating discoveries from life sciences research into actionable clinically relevant insights,” commented Chris Yoo, Chief Executive Officer of Systems Imagination.

“We are excited to announce our partnership with 3Scan, a company we believe is going to revolutionize how we view and reconstruct histopathology images. Together, we will be able to provide the pharmaceutical industry with a streamlined solution for more powerful analytical approaches to research and understand the molecular basis of diseases and how the development of innovative therapies they are bringing to market can be accelerated.”

SII UltraHigh Definition Translational Medicine service offering enables pharmaceutical companies to conduct comprehensive multiscalar genomic analyses for clinical drug development with corresponding high resolution, 3dimensional reconstructed histopathology image data in an integrated, streamlined solution. This will lead to the optimization of the phenotypic and genotypic characterization of biopsied samples, reducing costs and delays in data analysis process.

“Biological problems and solutions are inherently multiscale, and we’re excited to be working with SII to combine genotypic and phenotypic data to help cure disease.” stated Todd Huffman, CEO of 3Scan, Inc.

Advertisement